Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Banks On Product Launches, OTC Switches For "Significant Growth"

This article was originally published in The Tan Sheet

Executive Summary

Perrigo is "poised for some significant growth" with $180 million in new product sales expected in the firm's current fiscal year, according to President and CEO Joseph Papa.

You may also be interested in...



Merck Looks To “Exploit” Switches With Exit From J&J Joint Venture

Merck gains flexibility to pursue Rx-to-OTC switches, such as allergy drug Clarinex and cholesterol treatment Zetia by exiting its OTC joint venture with Johnson & Johnson.

Merck Looks To “Exploit” Switches With Exit From J&J Joint Venture

Merck gains flexibility to pursue Rx-to-OTC switches, such as allergy drug Clarinex and cholesterol treatment Zetia by exiting its OTC joint venture with Johnson & Johnson.

Merck Looks To “Exploit” Switches With Exit From J&J Joint Venture

Merck gains flexibility to pursue Rx-to-OTC switches, such as allergy drug Clarinex and cholesterol treatment Zetia by exiting its OTC joint venture with Johnson & Johnson.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS104804

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel